Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 25Neoplasms 12Prostatic Neoplasms 9Multiple Myeloma 9Neoplasm Metastasis 7Giant Cell Tumor of Bone 7Osteoporosis 4Fractures, Bone 4Recurrence 3Kidney Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Bone Diseases, Metabolic 3Bone Diseases 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Bone Neoplasms 2Bone Metastases 2Bone Cysts, Aneurysmal 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Paraproteinemias 1Pancreatic Neoplasms 1

Interventions

Denosumab 2radium Ra 223 dichloride 1Radiotherapy 1Radiation 1QL1206 1Magnetic Resonance Spectroscopy 1Hydroxychloroquine 1Fentanyl 1Exercise 1Docetaxel 1Continuous Glucose Monitoring 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bone Metastases × Denosumab × Clear all
NCT04812509 2023-02-24

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Completed
708 enrolled

Bone Metastases

NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
700 enrolled

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡